| 301337 | 亚华电 | 9.63 | 11.84 | 29.14 | 30.16 | 3.51 | | --- | --- | --- | --- | --- | --- | --- | | | 子 | | | | | | | 002081 | 金螳螂 | 3.80 | 1.76 | 3.44 | 3.55 | 3.32 | | 688161 | 威高骨 | 3.87 | 0.20 | 28.10 | 29.00 | 3.21 | | | 科 | | | | | | | 300485 | 赛升药 业 | 3.50 | 1.66 | 10.62 | 10.95 | 3.1 1 | | | 国电南 | | | | | | | 600406 | 瑞 | 3.07 | 0.44 | 22.49 | 23.17 | 3.00 | | 300678 | 中科信 | 13.78 | 8.78 | 33.99 | 35.00 | 2.97 | | | 息 | | | | | | | 002254 | 泰和新 | 4.09 | 1.51 | 10.14 | 10.43 | 2.82 | | | 材 | | | | | ...

每经AI快讯，1月5日，脑机接口概念盘中持续扩大涨幅，博拓生物、航天长峰（600855）封涨停，此 前倍益康、三博脑科（301293）、翔宇医疗、伟思医疗、诚益通（300430）等近20股涨停，冠昊生物 （300238）、狄耐克（300884）、中科信息（300678）、汉威科技（300007）、道氏技术（300409）等 多股涨超10%。 ...

证券日报网讯12月15日，冠昊生物（300238）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东总户数为28960户。 ...

Group 1 - The core point of the article is that Guanhao Biological has established a subsidiary, Beijing Tianyou Qiyuan Biotechnology Co., Ltd., in March 2025 as part of its strategic development and business planning [2] Group 2 - The establishment of the subsidiary is aligned with the company's operational needs [2]

Group 1 - The core point of the article is that Guanhao Biological (300238) reported a total of 29,672 shareholders as of November 28, 2025 [1]

交易所数据显示，11月24日，冠昊生物收盘15.29元，上涨5.38%，滚动市盈率PE（当前股价与前四季度 每股收益总和的比值）达到154.16倍，总市值40.54亿元。 最新一期业绩显示，2025年三季报，公司实现营业收入2.93亿元，同比增加5.52%；净利润2671.85万 元，同比减少4.02%，销售毛利率77.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13冠昊生物154.16147.877.0940.54亿行业平均 52.1952.084.44109.78亿行业中值40.1437.372.7954.98亿1九安医疗10.2111.560.87192.85亿2康德莱 15.2317.241.3937.13亿3英科医疗15.4517.951.45263.10亿4奥美医疗15.5519.081.8970.36亿5维力医疗 15.7817.571.9938.56亿6安杰思17.2416.041.8947.05亿7新华医疗17.7313.041.1490.21亿8山东药玻 17.7414.391.67135.71亿9奥泰生物17.7717.311.3452.37亿10九强生物18.171 ...

（文章来源：证券日报） 证券日报网讯冠昊生物11月24日在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东总 户数为29645户。 ...

Core Viewpoint - Guanhao Biological has shown a mixed performance in stock price, with a year-to-date increase of 23.26% but a recent decline over the past five, twenty, and sixty days [1][2]. Company Overview - Guanhao Biological Technology Co., Ltd. was established on October 22, 1999, and listed on July 6, 2011. The company is located in Huangpu District, Guangzhou, Guangdong Province [1]. - The main business involves research, production, and sales of regenerative medical materials and implantable medical devices, as well as cell therapy technology development, preparation, clinical application, and immune cell storage [1]. - The revenue composition is as follows: medical devices 73.28%, pharmaceuticals 15.21%, and leasing and other services 11.51% [1]. Financial Performance - For the period from January to September 2025, Guanhao Biological achieved an operating income of 293 million yuan, representing a year-on-year growth of 5.52%. However, the net profit attributable to the parent company was 26.72 million yuan, a decrease of 4.02% year-on-year [2]. - The company has cumulatively distributed 86.66 million yuan since its A-share listing, with no distributions in the past three years [3]. Shareholder Information - As of November 10, 2025, the number of shareholders for Guanhao Biological was 29,600, an increase of 4.20% from the previous period. The average circulating shares per person decreased by 4.03% to 8,951 shares [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 1.31 million shares [3]. Market Activity - On November 24, the stock price increased by 2.27% to 14.84 yuan per share, with a trading volume of 9.44 million yuan and a turnover rate of 0.24%. The total market capitalization is 3.935 billion yuan [1]. - The net inflow of main funds was 856,700 yuan, with large orders accounting for 11.99% of total purchases [1].

（编辑 袁冠琳） 证券日报网讯 冠昊生物11月17日在互动平台回答投资者提问时表示，安润®可降解泪小管栓是公司子公 司聚明生物自主研发的新一代干眼治疗产品，适用于角膜屈光、白内障等手术源性干眼的临时性泪道封 闭治疗。目前业务处于起步阶段，未来经营情况存在一定的不确定性，请投资者理性投资，注意风险。 公司将积极把握市场机遇，提升产品竞争力。公司产品研发方面的进展以及市场竞争力详情敬请关注公 司定期报告。 ...

证券日报网讯 冠昊生物（300238）11月17日在互动平台回答投资者提问时表示，安润 可降解泪小管栓 是公司子公司聚明生物自主研发的新一代干眼治疗产品，适用于角膜屈光、白内障等手术源性干眼的临 时性泪道封闭治疗。目前业务处于起步阶段，未来经营情况存在一定的不确定性，请投资者理性投资， 注意风险。公司将积极把握市场机遇，提升产品竞争力。公司产品研发方面的进展以及市场竞争力详情 敬请关注公司定期报告。 ...